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Following Uncomplicated Transcatheter Aortic Valve Implantation
Objectives This study sought to: 1) determine the incidence, degree, and timing of the rise in serum cardiac markers of
myocardial injury associated with uncomplicated transcatheter aortic valve implantation (TAVI); and 2) evaluate
the predictive factors and prognostic value of myocardial injury associated with TAVI.
Background Very few data exist on the occurrence and clinical relevance of myocardial injury during TAVI procedures.
Methods A total of 101 patients who underwent successful TAVI (transfemoral [TF] approach, n  38; transapical [TA]
approach, n  63) were included. Creatine kinase-MB (CK-MB) and cardiac troponin T (cTnT) levels were deter-
mined at baseline and at 6 to 12, 24, 48, and 72 h following TAVI.
Results TAVI was associated with some degree of myocardial injury in 99% of the patients (TF: 97%, TA: 100%) as determined by a
rise in cTnT (maximal value, 0.48 g/l, interquartile range [IQR]: 0.24 to 0.82 g/l) and in 77% of the patients (TF: 47%,
TA: 95%) as determined by a rise in CK-MB (maximal value, 18.6 g/l; IQR: 11.0 to 27.4 g/l). TA approach and baseline
renal dysfunction were associated with a higher increase in biomarkers of myocardial injury (p 0.01 for both). A larger
myocardial injury was associated with a smaller improvement of left ventricular ejection fraction (LVEF) (p  0.01).
The degree of rise in cTnT was an independent predictor of cardiac mortality at 9  10 months of follow-up (hazard
ratio: 1.14 per each increase of 0.1 g/l, 95% confidence interval: 1.02 to 1.28, p  0.028).
Conclusions TAVI was systematically associated with some degree of myocardial injury, with TA approach and baseline renal
dysfunction determining a higher increase in biomarkers of myocardial injury. A greater degree of myocardial
injury was associated with less improvement in LVEF and a higher cardiac mortality at follow-up. (J Am Coll
Cardiol 2011;57:1988–99) © 2011 by the American College of Cardiology Foundationa
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9Periprocedural myocardial infarction is one of the potential
complications associated with transcatheter aortic valve im-
plantation (TAVI) (1). However, most reports on TAVI to
ate have not provided a definition for periprocedural myocar-
ial infarction (1–4), and some studies have used an arbitrary
efinition of periprocedural myocardial infarction such as an
ncrease in creatine kinase-MB (CK-MB) 2 to 10 times the
upper normal limit (5–7), or the same definition as that used
for spontaneous myocardial infarction (8). Apart from the rare
occurrence of coronary complications, such as coronary ostia
occlusion following valve prosthesis implantation that would
lead to myocardial damage (9), uncomplicated TAVI proce-
ures could also be associated with a rise in cardiac markers of
yocardial injury. The procedure involves some degree of
yocardial tissue compression caused by the balloon and valve
rosthesis as well as several short episodes of extreme hypo-
ension and global ischemia (balloon valvuloplasty, valve im-
lantation) that might induce some degree of myocardial
njury. Also, the transapical (TA) approach, which is an
lternative to the transfemoral (TF) approach (2,3,8), involves
he puncture of the ventricular apex and the introduction of
arge catheters through it. The objectives of this study were:
) to determine the incidence, degree, and timing of the rise
n serum markers of myocardial injury (CK-MB and cardiac
roponin T [cTnT]) associated with uncomplicated TAVI
TA and TF); and 2) to evaluate the predictive factors and
rognostic value of myocardial injury associated with TAVI.
ethods
he study population consisted of 101 patients who underwent
uccessful uncomplicated TAVI (TF approach: n  38; TApproach: n 63) in our center. Patients who died within the
4 h following the procedure precluding cardiac biomarker
easurements (n  5), and those with major procedural
omplications (need for hemodynamic support with extra-
orporeal circulation: n  6; conversion to open heart surgery:
n 3; myocardial tears during left ventricular apex repair: n
; life-threatening arrhythmias during the procedure: n  7)
were excluded. Selection of TF or TA approaches was based on
the appropriateness of the iliofemoral arteries (10). All patients
were included in a registry, and baseline and procedural
characteristics variables were prospectively recorded. Patients
with coronary artery disease were divided into those with and
those without complete revascularization before TAVI. In-
complete revascularization was defined as the presence of an
obstructive lesion (70% diameter stenosis, visual estimation)
in 1 of the 3 main coronary vessels and main branches that was
not treated before TAVI. The decision on whether or not to
revascularize a vessel with an obstructive coronary lesion
depended on the criteria of the physician responsible for the
patient and the TAVI team. An electrocardiogram (ECG) was
performed within 24 h before TAVI, immediately after the
procedure, and at hospital discharge. All ECGs were evaluated
for the purpose of the study by a cardiologist blinded to clinical
data. All patients had continuous ECG monitoring until
hospital discharge. A Doppler echocardiography was per-
formed before the procedure and at hospital discharge. All
procedures were performed under a Compassionate Clinical
Program approved by Health Canada, and all patients pro-
vided signed informed consent for the procedures.
The TAVI procedures have been extensively detailed in
previous studies (10). All procedures were performed with the
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Myocardial Injury During TAVI May 17, 2011:1988–99Edwards valve (Edwards SAPIEN
or SAPIEN XT, Edwards Life-
sciences Inc., Irvine, California).
Measurements of the serum
markers of myocardial injury.
Blood samples were collected at 6
to 12, 24, 48, and 72 h following
the procedure. CK-MB mass and
cTnT levels were measured at each
point time. CK-MB and cTnT
measurements were performed by
electrochemiluminescence im-
munoassay (Roche, Minneapolis,
Minnesota). Based on the 99th
percentile in a healthy population
and the requirement of a 10%
coefficient variation, the upper
normal limits for CK-MB and
cTnT levels in our institution were 10 and 0.03 g/l, respec-
tively. Myocardial injury was defined as a CK-MB level 10
g/l or a cTnT level 0.04 g/l. In those patients with
levated CK-MB or cTnT levels at baseline, myocardial injury
as defined as any increase 20% after the procedure (11).
Figure 1 Changes in Serum Markers of Myocardial Injury Follow
Changes in creatine kinase-myocardial band (CK-MB) and cardiac troponin T (cTnT
in all patients (A) and grouped according to the approach (transfemoral [TF], trans
Abbreviations
and Acronyms
CI  confidence interval
CK-MB  creatine
kinase-MB
cTnT  cardiac troponin T
ECG  electrocardiogram
IQR  interquartile range
LVEF  left ventricular
ejection fraction
ROC  receiver-operating
characteristic
TA  transapical
TAVI  transcatheter aortic
valve implantation
TF  transfemoralollow-up. Clinical follow-up was carried out by clinical
isits or through telephone contact. Patients were followed
t 1, 6, and 12 months after the procedure and annually
hereafter. Doppler echocardiography was performed at
-month to 1-year follow-up. Death at any time during the
ollow-up period was recorded and further classified as of
ardiac or noncardiac origin.
tatistical analysis. Continuous variables are expressed as
ean  SD or median (25th to 75th interquartile range
IQR]) depending on variable distribution. Group compari-
ons were analyzed using the Student t test or Wilcoxon rank
um test for continuous variables, and chi-square test for
ategorical variables. An analysis of variance for repeated
easures was performed to test for equal means at different
imes (baseline, 6 to 12, 24, 48, and 72 h) for the cardiac
nzyme values, and a 2-way analysis of variance for repeated
easures with interaction was used to compare the changes in
ardiac enzyme levels at different time points between groups
TF-TAVI vs. TA-TAVI; complete vs. incomplete revascu-
arization before TAVI). The covariance among repeated
easures was modeled using a compound symmetry structure,
hich indicated that the correlations between all pairs of
easures were the same. The variables associated with a
TAVI
within the 72 h following transcatheter aortic valve implantation (TAVI)
[TA]) (B). Values are expressed as median (25th to 75th interquartile range).ing
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May 17, 2011:1988–99 Myocardial Injury During TAVIgreater myocardial injury were determined by univariate anal-
ysis, and those variables with a p value 0.10 were entered in
stepwise linear regression analysis. Relationships between
ardiac enzyme and left ventricular changes were expressed
ith the Spearman correlation. The univariate normality as-
umptions were verified with the Shapiro-Wilk tests. The
ultivariate normality assumptions were verified with the
Clinical, Echocardiographic, and Procedural Cha(n  101)Table 1 Clinical, Echo ardiographic, and Pr(n  101)
Variables
All Pa
(n 
Clinical variables
Age, yrs 79
Male 43 (
BMI, kg/m2 26
Diabetes 45 (
Dyslipidemia 81 (
Hypertension 93 (
Current smokers 7 (
NYHA functional class
I–II 6 (
III–IV 95 (
Chronic atrial fibrillation/flutter 11 (
Prior coronary artery disease 63 (
Complete revascularization before TAVI 42 (
Incomplete revascularization before TAVI 21(
Cerebrovascular disease 26 (
Peripheral vascular disease 35 (
COPD 28 (
Creatinine, mol/l 127
eGFR 60 ml/min 68 (
Dialysis 2 (
STS-PROM score, % 8.3
Porcelain aorta 22 (
Frailty 13 (
Echocardiographic data
Mean aortic gradient, mm Hg 42
Aortic valve area, cm2 0.62
LVEF, % 56
LVEF 40% 13 (
Pulmonary hypertension 10 (
Procedural variables
Time of procedure “skin to skin,” min 76
Contrast amount, ml 20 (
Rapid pacing runs 5
Prosthesis size, mm
23 58 (
26 26 (
Valve size/aortic annulus size 1.17
Successful procedure 101 (
30-day outcomes
Stroke 4 (
Need for hemodialysis 1 (
Need for permanent pacemaker 6 (
30-day mortality 6 (
Values are expressed as mean  SD, n (%), or median (25th to 75th
BMI  body mass index; COPD  chronic obstructive pulmonary d
ejection fraction; NYHA New York Heart Association; STS-PROM S
aortic valve implantation.hapiro-Wilk tests after a Cholesky factorization. The Brown mand Forsythe variation of the Levene test statistic was used to
verify the homogeneity of variances. Cardiac enzyme values
were log transformed to fulfill the normality and variances
assumptions. Receiver-operating characteristic (ROC) curve
analysis was performed to discriminate power of the cardiac
enzyme rise for a left ventricular ejection fraction (LVEF)
decrease at 6- to 12-month follow-up ( 0 vs.  0). A
ristics of the Study Populational Charact ris ics of the Study Population
Transfemoral
(n  38)
Transapical
(n  63) p Value
82 6 78 9 0.006
21 (56) 22 (35) 0.06
27 5 26 4 0.26
18 (47) 27 (43) 0.68
28 (74) 53 (84) 0.21
33 (87) 60 (95) 0.15
3 (8) 4 (6) 1.00
4 (11) 2 (3) 0.28
34 (89) 61 (97)
3 (30) 8 (14) 0.35
21 (58) 42 (67) 0.52
14 (67) 28 (67) 1.00
7 (33) 14 (33)
9 (17) 17 (27) 0.82
7 (18) 28 (44) 0.009
9 (24) 19 (30) 0.65
124 63 130 10 0.70
25 (66) 43 (68) 0.83
0 2 (3) 0.53
8.0 5.2 8.6 6.5 0.68
4 (11) 18 (29) 0.05
8 (21) 5 (8) 0.07
42 12 42 19 0.92
0.62 0.13 0.62 0.21 0.98
58 2 54 14 0.12
3 (8) 10 (16) 0.36
5 (14) 5 (9) 0.51
86 26 70 15 0.001
) 36 (25–60) 12 (10–20) 0.0001
5 2 6 2 0.0001
18 (47) 40 (63) 0.15
20 (53) 23 (37) 0.15
1.17 0.10 1.17 0.07 0.91
38 (100) 63 (100) —
2 (6) 2 (3) 0.62
0 1 (2) 1.00
3 (8) 3 (5) 0.67
2 (5) 4 (6) 1.00
artile range).
eGFR  estimated glomerular filtration rate; LVEF  left ventricular
f Thoracic Surgeons Predicted Risk Of Mortality; TAVI transcatheterracteocedu
tients
101)
 8
43)
 5
45)
81)
93)
7)
6)
95)
11)
64)
67)
33)
26)
35)
28)
 74
68)
2)
 6.0
22)
13)
 17
 0.19
13
13)
10)
 21
10–40
 2
58)
43)
 0.08
100)
4)
1)
6)
6)
interqu
isease;ultivariate Cox regression analysis was used to determine the
u
I
R
T
i
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Myocardial Injury During TAVI May 17, 2011:1988–99variables predictive of cumulative mortality at follow-up, in-
cluding all baseline and procedural variables with a p value
0.10 in the univariate analysis. The results were considered
significant with p values 0.05. All analyses were conducted
sing the statistical package SAS version 9.2 (SAS Institute
Degree of CK-MB and cTnT Increase Following TProc dural CharacteristicsTable 2 Degree of CK-MB and cTnT IncreasProcedural Characteristics
Variables 
Clinical variables
Age, yrs
Median (80 yrs) 0.67 (0
Median (80 yrs) 0.41 (0
Sex
Male 0.43 (0
Female 0.55 (0
BMI, kg/m2
Median (25 kg/m2) 0.40 (0
Median (25 kg/m2) 0.58 (0
Diabetes
Yes 0.41 (0
No 0.64 (0
Dyslipidemia
Yes 0.48 (0
No 0.65 (0
Hypertension
Yes 0.52 (0
No 0.15 (0
Current smokers
Yes 0.61 (0
No 0.49 (0
Coronary artery disease
Yes 0.48 (0
No 0.56 (0
Prior coronary artery disease
Complete revascularization before TAVI 0.50 (0
Incomplete revascularization before TAVI 0.36 (0
Cerebrovascular disease
Yes 0.68 (0
No 0.47 (0
COPD
Yes 0.48 (0
No 0.50 (0
Creatinine, mol/l
Median (107 mol/l) 0.68 (0
Median (107 mol/l) 0.37 (0
eGFR, ml/min
60 0.37 (0
60 0.66 (0
STS-PROM score, %
Median (7%) 0.58 (0
Median (7%) 0.47 (0
Porcelain aorta
Yes 0.50 (0
No 0.51 (0
Frailty
Yes 0.27 (0
No 0.56 (0nc., Cary, North Carolina). cesults
he clinical, echocardiographic, and procedural character-
stics of the entire study population and the TF and TA
roups are shown in Table 1. Mean aortic gradient de-
Depending on Baseline andlowing TAVI Depend g o Baseline and
p Value CK-MB p Value
.10) 0.08 15.3 (7.5–26.5) 0.09
.65) 10.9 (6.9–15.8)
.99) 0.47 11.1 (6.6–18.0) 0.11
.82) 15.3 (8.5–24.4)
.84) 0.19 13.7 (6.9–22.2) 0.64
.87) 11.5 (6.3–18.7)
.67) 0.21 12.4 (6.9–17.2) 0.58
.99) 15.4 (5.4–24.4)
.87) 0.26 11.5 (6.3–17.3) 0.19
.90) 16.2 (8.5–23.0)
.90) 0.09 13.1 (6.9–20.3) 0.44
.65) 6.5 (4.7–24.4)
.94) 0.77 11.0 (5.5–17.7) 0.58
.86) 13.1 (6.9–22.1)
.82) 0.57 12.7 (6.3–17.3) 0.26
.90) 15.5 (8.7–28.4)
.82) 0.71 13.0 (5.4–22.3) 0.73
.95) 11.5 (6.9–17.3)
.13) 0.09 13.0 (11.3–17.2) 0.81
.80) 12.8 (6.2–23.0)
.87) 0.65 13.4 (6.9–18.0) 0.50
.84) 13.0 (6.3–22.3)
.10) 0.003 14.3 (6.2–20.3) 0.87
.64) 11.8 (6.9–22.2)
.55) 0.005 13.1 (7.5–22.1) 0.96
.07) 12.7 (6.3–20.3)
.03) 0.24 14.2 (6.2–18.7) 0.97
.76) 11.3 (7.5–22.3)
.77) 0.83 13.4 (8.7–28.4) 0.30
.94) 12.7 (5.8–18.0)
.50) 0.09 11.3 (5.4–15.1) 0.28
.87) 13.6 (6.9–22.3)
Continued on next pageAVIe Fol
cTnT
.16–1
.24–0
.16–0
.33–0
.20–0
.36–0
.23–0
.27–0
.20–0
.40–0
.28–0
.10–0
.28–0
.23–0
.23–0
.27–0
.19–0
.23–0
.33–1
.23–0
.27–0
.20–0
.38–1
.20–0
.20–0
.29–1
.25–1
.22–0
.34–0
.20–0
.15–0
.29–0reased from 42  17 mm Hg at baseline to 9  3 mm Hg
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May 17, 2011:1988–99 Myocardial Injury During TAVIafter TAVI, and aortic valve area increased from 0.62 
0.19 cm2 at baseline to 1.65  0.24 cm2 after TAVI. Some
degree of residual aortic regurgitation occurred in 75 pa-
tients (74%), and was trivial, mild, and moderate in 33%,
35%, and 6% of the cases, respectively.
Serum markers of myocardial injury following TAVI.
The mean values of CK-MB and cTnT at each time point
within the 72 h following the procedure for the entire study
population and for the TF- and TA-TAVI groups are
shown in Figure 1. CK-MB level was within normal limits
in all patients at baseline and increased above the upper
normal limit in 77% of the patients with a median peak of
18.6 g/l (IQR: 11.0 to 27.4 g/l) at 24 h following the
procedure and returned to baseline values at 72 h after
TAVI. In the TA-TAVI group, the CK-MB levels were
above the upper normal values in 95% of the patients
compared with 47% of the patients in the TF-TAVI group
(p  0.0001). The degree of CK-MB increase was also
higher in the TA-TAVI group compared with the TF-
TAVI group at all time points following the procedure (p
0.0001) (Fig. 1B), and the median maximal value of
ContinuedTable 2 Continued
Variables cTn
Echocardiographic data
Mean aortic gradient, mm Hg
Median (41 mm Hg) 0.49 (0.21
Median (41 mm Hg) 0.54 (0.29
Aortic valve area, cm2
Median (0.6 cm2) 0.47 (0.19
Median (0.6 cm2) 0.53 (0.30
LVEF, %
40 0.49 (0.22
40 0.68 (0.34
Pulmonary hypertension
Yes 0.49 (0.24
No 0.51 (0.21
Procedural variables
Approach
Transfemoral 0.16 (0.08
Transapical 0.68 (0.45
Time of procedure “skin to skin,” min
Median (74 min) 0.42 (0.16
Median (74 min) 0.58 (0.34
Contrast amount, ml
Median (20 ml) 0.41 (0.16
Median (20 ml) 0.64 (0.36
Rapid pacing runs
Median (6) 0.63 (0.39
Median (6) 0.33 (0.15
Prosthesis size, mm
23 0.50 (0.27
26 0.49 (0.19
Valve size/aortic annulus size
Median (1.15) 0.59 (0.36
Median (1.15) 0.39 (0.15
Values are expressed as median (25th to 75th interquartile range), u
Abbreviations as in Table 1.CK-MB in the TA-TAVI group within the 72 h following vthe procedure was 22.6 g/l (IQR: 16.3 to 32.4 g/l)
ompared with 9.9 g/l (IQR: 6.4 to 13.4 g/l) in the
F-TAVI group (p  0.0001). The increase in CK-MB
evels grouped according to the degree of rise in CK-MB
ollowing TAVI in the entire study population and in the
F-TAVI and TA-TAVI groups is shown in Figure 2.
The cTnT levels were within the normal limits at baseline
n 85% of the patients and increased above the upper normal
imit in all patients but 1 (1%) following TAVI, with a
edian peak of 0.48 g/l (IQR: 0.24 to 0.82 g/l) at 48 h
ollowing the procedure (Fig. 1A). The cTnT values con-
inued to be above baseline values at 72 h following TAVI
Fig. 1A). In the TF-TAVI group, the peak of cTnT was at
to 12 h after the procedure, whereas in the TA-TAVI
roup, it occurred at 48 h after the procedure. cTnT levels
ncreased to above the upper normal values in all patients in
he TA-TAVI group compared with 97% of the patients in
he TF-TAVI group (p  0.38). The degree of cTnT
ncrease was higher in the TA-TAVI group compared with
he TF-TAVI group at all time points following the
rocedure (p  0.0001) (Fig. 1B). The median maximal
p Value CK-MB p Value
) 0.51 11.5 (6.2–15.5) 0.32
) 16.3 (7.5–24.4)
) 0.61 14.3 (6.3–22.6) 0.90
) 11.5 (6.9–17.3)
) 0.23 12.6 (6.9–20.3) 0.75
) 15.8 (8.1–22.9)
) 0.90 7.8 (4.7–11.5) 0.36
) 13.1 (6.9–20.3)
) 0.0001 6.3 (3.1–11.3) 0.0001
) 16.5 (12.7–27.5)
) 0.44 7.45 (4.1–18.8) 0.08
) 15.1 (9.6–22.3)
) 0.03 8.7 (4.7–17.3) 0.03
) 15.2 (10.9–24.4)
) 0.005 16.4 (11.5–26.5) 0.007
) 8.5 (5.4–14.3)
) 0.71 14.0 (8.1–23.0) 0.27
) 11.7 (5.5–19.5)
) 0.007 15.5 (11.5–23.0) 0.002
) 7.2 (3.5–17.9)
herwise noted.T
–0.84
–0.98
–0.92
–0.81
–0.82
–1.33
–0.85
–0.87
–0.31
–1.04
–0.99
–0.81
–0.80
–1.00
–0.94
–0.77
–0.82
–0.94
–1.12
–0.77alue of cTnT in the TF-TAVI group within the 72 h
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Myocardial Injury During TAVI May 17, 2011:1988–99following the procedure was 0.19 g/l (IQR: 0.13 to 0.31
g/l) compared with 0.74 g/l (IQR: 0.48 to 1.07 g/l) in
the TA-TAVI group (p  0.0001). The increase in cTnT
levels grouped according to the degree of rise in cTnT
following TAVI in the entire study population and in the
TF-TAVI and TA-TAVI groups is shown in Figure 2B.
One patient (1%) developed new Q waves in the inferior
leads in the ECG following the procedure. No life-
threatening ventricular arrhythmia occurred during the hos-
pitalization period.
Predictors of myocardial injury following TAVI. The
degree of myocardial injury depending on baseline and
procedural characteristics of the entire study population is
shown in Table 2. In the multivariate analysis, TA-TAVI
was the only independent predictor of a higher rise in
CK-MB following the procedure (r2  0.24, p  0.0001),
and TA-TAVI and baseline renal dysfunction were the 2
independent predictors of a higher rise in cTnT following
the procedure (r2 0.30, p 0.0001, r2 0.07, p 0.003,
or TA-TAVI and renal dysfunction, respectively).
The rise in CK-MB and cTnT levels at each time point
ithin the 72 h following the procedure grouped according
o the presence of coronary artery disease and the complete-
ess of coronary revascularization before TAVI is shown in
igure 3. Patients with prior coronary artery disease exhibited
rise in cardiac markers similar to those without coronary
rtery disease (maximal CK-MB levels: 18 g/l [IQR: 10.9 to
26.6 g/l] vs. 19.3 g/l [IQR: 11.3 to 31.6 g/l], p  0.61;
Figure 2 Degree of Increase in CK-MB and cTnT Levels Followi
Cardiac biomarker changes following TAVI are grouped according to the degree of
Abbreviations as in Figure 1.aximal cTnT levels: 0.49 g/l [IQR: 0.25 to 0.81 g/l] vs. 00.43 g/l [IQR: 0.21 to 0.87 g/l], p  0.99). Among the
patients with a history of coronary artery disease, those who
had complete revascularization prior to TAVI exhibited a rise
in cardiac markers similar to those without complete revascu-
larization (maximal CK-MB levels: 18.6 g/l [IQR: 11.0 to
6.7 g/l] vs. 16.3 g/l [IQR: 10.8 to 25.9 g/l], p  0.99;
aximal cTnT levels: 0.51 g/l [IQR: 0.24 to 0.81 g/l] vs.
0.37 g/l [IQR: 0.27 to 0.81 g/l], p  0.67).
rognostic value of myocardial injury. A total of 6
atients (5.9%) died within the 30 days following the
rocedure. These patients tended to exhibit a greater in-
rease in cTnT levels (0.98 g/l [IQR: 0.38 to 1.33 g/l])
following TAVI than those who survived (0.48 g/l [IQR:
0.23 to 0.82 g/l], p  0.19). There were no differences in
CK-MB rise between patients who had died and those who
had survived at 30-day follow-up (15.1 g/l [IQR: 6.2 to
26.5 g/l] vs. 12.9 g/l [IQR: 6.9 to 20.3 g/l], p  0.83).
At a mean follow-up of 9  10 months, a total of 19
patients had died. Of these, 10 patients died during the
follow-up period of noncardiac causes (respiratory 4, cancer
3, renal failure  2, sepsis  1). Baseline and procedural
characteristics of the patients grouped according to the occur-
rence of global (cardiac and noncardiac) and cardiac cumulative
death at follow-up are shown in Tables 3 and 4, respectively. In
he multivariate analysis, the degree of increase in cTnT was
dentified as the independent predictor of cardiac mortality
t follow-up (hazard ratio: 1.14 for each increase in cTnT of
.1 g/l, 95% confidence interval [CI]: 1.02 to 1.28, p 
VI
(A) and cTnT (B) increase in all patients and in the TF and TA approach groups.ng TA
CK-MB.028). A cTnT level0.60 g/l was identified as the cutoff
h

C
b
C
s
b
r
1995JACC Vol. 57, No. 20, 2011 Rodés-Cabau et al.
May 17, 2011:1988–99 Myocardial Injury During TAVIpoint with the best sensitivity and specificity for the predic-
tion of cumulative cardiac death following uncomplicated
TAVI, with an area under the ROC curve of 0.65 (95% CI:
0.40 to 0.89, p  0.015). The sensitivity and specificity of a
cTnT 0.60 g/l for the prediction of cardiac mortality
following TAVI were 67% and 62%, respectively.
The LVEF as determined by echocardiography at 6- to
12-month follow-up was available in 39 of the 46 patients
(85%) with a follow-up 6 months. The LVEF tended to be
igher at follow-up compared with baseline (58  13% vs. 56
13%, p 0.13). The correlation between the increase () in
K-MB and cTnT and the changes in LVEF between
aseline and follow-up are shown in Figure 4. The increase in
K-MB and cTnT levels following the procedure exhibited a
ignificant correlation with the changes in LVEF between
aseline and follow-up (r  0.41, p  0.009 for CK-MB;
0.46, p 0.003 for cTnT). A CK-MB level26 g/l
was identified as the cutoff point with the best sensitivity
and specificity for the prediction of LVEF decrease follow-
ing uncomplicated TAVI, with an area under the ROC
curve of 0.74 (95% CI: 0.579 to 0.90, p  0.026). The
sensitivity and specificity of a CK-MB level 26 g/l for
the prediction of LVEF deterioration at follow-up were
72% and 64%, respectively. A cTnT level 0.48 g/l was
identified as the cutoff point with the best sensitivity and
Figure 3 Coronary Artery Disease, Coronary Revascularization
Changes in CK-MB and cTnT levels within the 72 h following TAVI grouped according t
before TAVI. Values are expressed as median (25th to 75th interquartile range). (A) Aspecificity for the prediction of LVEF decrease followingTAVI, with an area under the ROC curve of 0.76 (95% CI:
0.61 to 0.92, p  0.018). The sensitivity and specificity of a
cTnT level 0.48 g/l for the prediction of LVEF deteri-
oration at follow-up were 64% and 79%, respectively.
Discussion
TAVI was systematically associated with some degree of
myocardial injury as determined by CK-MB and cTnT
release following the procedure. TA-TAVI was associated
with an increase in CK-MB and cTnT levels about 2 and 4
times higher, respectively, than that observed after TF-
TAVI. TA-TAVI and baseline renal dysfunction predicted
a higher increase in biomarkers of myocardial injury after
the procedure. The presence of prior coronary artery disease
was not associated with a higher degree of myocardial
injury, and no differences were observed between those
patients with and without complete revascularization before
the procedure. Finally, a higher degree of myocardial injury
was associated with a lesser improvement in LVEF and a
higher cardiac mortality at midterm follow-up.
Very few previous studies on TAVI have reported data on
the occurrence of myocardial injury following TAVI. Grube
et al. (5) and Buellesfeld et al. (6) reported an incidence of
1.5% to 1.8% of CK-MB elevation 2 times the upper
leteness Prior to TAVI, and Degree of Myocardial Injury
resence of coronary artery disease and coronary revascularization completeness
nts. (B) TF approach group. (C) TA approach group. Abbreviations as in Figure 1.Comp
o the p
ll patienormal limit following TF-TAVI. Svensson et al. (8)
ange).
reviatio
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Myocardial Injury During TAVI May 17, 2011:1988–99showed that 17% of the patients who underwent TA-TAVI
had a periprocedural myocardial infarction as determined by
using the definition of spontaneous myocardial infarction
(11). Also following TA-TAVI, we have previously re-
ported an increase in CK-MB values 5 times the upper
normal limit in 6% of the patients (12). The present study,
which is the first to our knowledge to systematically evaluate
the degree of myocardial injury associated with uncompli-
cated TAVI, has shown that the procedure was associated
with some degree of myocardial injury in 99% of the
Baseline and Procedural Characteristics of theto the Occurrence of Cumul tive Mortality (CardTable 3 Baseline and Procedu al Charact ito the Occurrence of Cumulative M
Variables
Clinical variables
Age, yrs
Male
BMI, kg/m2
Diabetes
Dyslipidemia
Hypertension
Current smokers
Chronic atrial fibrillation/flutter
Prior coronary artery disease
Complete revascularization before TAVI
Incomplete revascularization before TAVI
Cerebrovascular disease
Peripheral vascular disease
COPD
Creatinine, mol/l
eGFR 60 ml/min
Dialysis
STSPROM score, %
Porcelain aorta
Frailty
Echocardiographic data
Mean aortic gradient, mm Hg
Aortic valve area, cm2
LVEF, %
LVEF 40%
Pulmonary hypertension
Procedural variables
Approach
Transfemoral
Transapical
Time of procedure “skin to skin,” min
Contrast amount, ml
Rapid pacing runs
Valve size/aortic annulus size
Cardiac biomarker rise, g/l
cTnT 0
CK-MB 1
30-day outcomes
Stroke
Need for hemodialysis
Need for permanent pacemaker
Values are mean  SD, n (%), or median (25th to 75th interquartile r
CK-MB  creatine kinase-MB; cTnT  cardiac troponin T; other abbpatients. The reasons for the occurrence of myocardialinjury in most patients undergoing TAVI are probably
multifactorial. The present study has shown that the main
procedural factor associated with a significant increase in
cardiac biomarker levels was the TA approach, which
involves the introduction of large catheters through the
ventricular apex. Also, the TAVI procedure is associated
with several episodes of extreme hypotension leading to
short periods of myocardial ischemia that could contribute
to the increase in CK-MB and cTnT levels after the
procedure. The use of a self-expandable valve such as the
Population, Accordingnd Noncardiac) at Follow-Upof the Stu y Population, According
ty (Cardiac and Noncardiac) at Follow-Up
Cumulative Mortality
 82) Yes (n  19) p Value
 8 81 9 0.29
(39) 11 (58) 0.20
 5 23 4 0.007
(44) 9 (47) 0.80
(78) 17 (89) 0.35
(93) 17 (89) 0.64
(4) 4 (21) 0.02
(16) 3 (20) 0.70
(61) 14 (74) 0.43
(61) 12 (86) 0.21
(39) 2 (14)
(21) 9 (47) 0.04
(33) 8 (42) 0.59
(22) 10 (53) 0.01
 77 141 62 0.39
(66) 14 (74) 0.60
(2) 0 1.00
 5 12 8 0.04
(23) 3 (16) 0.55
(15) 1 (5) 0.45
 18 32 9 0.001
 0.19 0.69 0.15 0.07
 13 49 15 0.01
(10) 5 (26) 0.07
(9) 3 (20) 0.36
(38) 1 (37) 1.00
(22) 12 (63) 1.00
 20 85 24 0.03
 27 30 33 0.93
 2 6 2 0.55
 0.08 1.17 0.08 0.99
23–0.82) 0.63 (0.38–1.23) 0.23
9–22.1) 13.2 (6.6–20.1) 1.00
(5) 0 1.00
(2) 0 1.00
(5) 2 (11) 0.32
ns as in Table 1.Studyiac as i s
ortali
No (n
79
32
27
36
64
76
3
8
50
30
19
17
27
18
124
54
2
8
19
12
45
0.60
57
8
7
31
51
74
29
5
1.17
.48 (0.
3.0 (6.
4
2
4CoreValve (Medtronic, Minnesota) avoids the rapid pacing
ange).
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May 17, 2011:1988–99 Myocardial Injury During TAVIand extreme hypotension during valve expansion, and this
might contribute to a reduction in myocardial injury (4–6).
On the other hand, TAVI involves some direct stretching of
the basal myocardial septum by the balloon expanding the
prosthesis and by the prosthesis itself. The balloon-valve
prosthesis is systematically overdimensioned with respect to
the aortic annulus, and interestingly, a higher degree of
overdimensioning was associated with a higher increase in
cTnT in our study, although this procedural variable was
not found to be an independent predictor of a higher degree
Baseline and Procedural Characteristics of theAccording to the Occurrence of Cumulative CarTable 4 Baseline and Procedu al Charact riAccording to the Occurrence of Cum
Variables
Clinical variables
Age, yrs
Male
BMI, kg/m2
Diabetes
Dyslipidemia
Hypertension
Current smokers
Chronic atrial fibrillation/flutter
Prior coronary artery disease
Complete revascularization before TAVI
Incomplete revascularization before TAVI
Cerebrovascular disease
Peripheral vascular disease
COPD
Creatinine, mol/l
eGFR 60 ml/min
Dialysis
STS-PROM score, %
Porcelain aorta
Frailty
Echocardiographic data
Mean aortic gradient, mm Hg
Aortic valve area, cm2
LVEF, %
LVEF 40%
Pulmonary hypertension
Procedural variables
Approach
Transfemoral
Transapical
Time of procedure “skin to skin,” min
Contrast amount, ml
Rapid pacing runs
Valve size/aortic annulus size
Cardiac biomarker rise, g/l
Cardiac troponin T 0
Creatine kinase-MB 1
30-day outcomes
Stroke
Need for hemodialysis
Need for permanent pacemaker
Values are mean  SD, n (%), or median (25th to 75th interquartile r
Abbreviations as in Tables 1 and 3.of myocardial injury following TAVI. Also, coronary em-bolism secondary to the embolization of small micropar-
ticles from the native aortic valve following the retrograde
crossing of the valve and especially during balloon valvulo-
plasty and valve implantation may be another potential
cause of myocardial injury in these patients. Among the
baseline characteristics, renal dysfunction was the only
predictor of a higher cTnT rise following the procedure. It
has been well demonstrated that renal dysfunction can be
associated with higher levels of cTnT (13), and it has been
shown that elevated cTnT levels and its changes (increase)
Population,ortalityof the Study Population,
ive Cardiac Mortality
Cumulative Cardiac Mortality
 92) Yes (n  9) p Value
8 81 10 0.51
(40) 6 (67) 0.16
 5 24 5 0.18
(42) 6 (67) 0.18
(80) 7 (78) 1.00
(92) 8 (89) 0.54
(5) 2 (22) 0.12
(15) 2 (33) 0.26
(63) 6 (67) 1.00
(63) 6 (100) 0.17
(37) 0
(24) 4 (44) 0.23
(33) 5 (56) 0.27
(24) 6 (67) 0.01
 77 153 43 0.29
(66) 7 (78) 0.71
(2) 0 1.00
 5 13 10 0.15
(22) 2 (22) 1.00
(13) 1 (11) 1.00
 17 34 11 0.11
 0.19 0.67 0.12 0.42
 13 51 15 0.33
(12) 2 (22) 0.33
(12) 0 1.00
(38) 3 (33) 1.00
(62) 6 (67) 1.00
 21 79 20 0.60
 28 25 30 0.64
 2 7 2 0.01
 0.08 1.17 0.08 0.85
23–0.82) 0.98 (0.49–1.41) 0.07
9–18.7) 19.0 (6.2–26.5) 0.53
(4) 0 1.00
(2) 0 1.00
(4) 2 (22) 0.09Studydiac Ms i s
ulat
No (n
79
37
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39
74
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125
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Myocardial Injury During TAVI May 17, 2011:1988–99of renal dysfunction (14,15). Interestingly, we did not find
any influence of the presence of prior coronary artery disease
and pre-procedural completeness of coronary revasculariza-
tion on myocardial injury following TAVI. Masson et al.
(16) recently showed the lack of prognostic value of com-
pleting coronary revascularization before TAVI. There has
been some debate about the usefulness of achieving a
complete revascularization in coronary patients undergoing
TAVI with no symptoms of angina. Although the very few
data available to date, including the present study, do not
support performing coronary interventions prior to the
TAVI procedure, future randomized studies will have to
determine the potential benefits of this strategy.
It has been extensively shown that the occurrence of
myocardial injury during cardiac procedures such as percu-
taneous coronary intervention or cardiac surgery is associ-
ated with worse acute and long-term outcomes (11,17). The
Figure 4 Myocardial Injury and LVEF Changes Following TAVI
Relationship between the maximal increase in CK-MB (A) and cardiac troponin T (
following transcatheter aortic valve implantation (TAVI).present study is the first to our knowledge to suggest that csignificant periprocedural myocardial injury has also a prog-
nostic value following TAVI procedures. The degree of
myocardial injury correlated with the changes in LVEF at
midterm follow-up, with a CK-MB increase of 26 g/l
nd cTnT of 0.48 g/l best determining LVEF deterio-
ation following TAVI. Also, the degree of myocardial
njury as determined by the increase in cTnT was associated
ith a higher cardiac mortality at midterm follow-up, with
troponin cutoff 0.60 g/l best determining the occur-
ence of cardiac death following uncomplicated TAVI.
lthough magnetic resonance imaging studies have shown
hat any increase in cardiac biomarkers following coronary
nterventions is associated with some degree of irreversible
yocardial damage (18), the definition of myocardial infarc-
ion following cardiac procedures has been based on the cardiac
nzyme threshold (CK-MB 3 and 5 times the upper
ormal limit for percutaneous coronary intervention and
ls and the changes in left ventricular ejection fraction (LVEF)B) leveardiac surgery, respectively), which best predicted a poor
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May 17, 2011:1988–99 Myocardial Injury During TAVIclinical outcome. Either no definition or arbitrary definitions
have been used to date for the diagnosis of periprocedural
myocardial infarction associated with TAVI (1–8). Our results
showed that a CK-MB increase of about 3 times the upper
normal limit and a cTnT increase of about 15 times the
upper normal limit following TAVI might be clinically rele-
vant, and suggest that these cardiac biomarker rise thresholds
might be appropriate to define the occurrence of periprocedural
myocardial infarction following TAVI.
Study limitations. In patients with prior coronary artery
isease, the decision to revascularize coronary obstructive
esions prior to TAVI depended on the criteria of the physician
esponsible for the patient and the TAVI team, with no
re-specified protocol. This might have introduced some bias
egarding the association between revascularization complete-
ess prior to and myocardial injury following TAVI. The small
ample size limits the conclusions regarding the results of the
ifferent subgroup analyses presented in this study. Therefore,
hese results will have to be confirmed by larger studies.
onclusions
ome degree of myocardial injury as determined by CK-MB
nd cTnT release occurred in the vast majority of patients
ndergoing TAVI, irrespective of the approach. TA-TAVI
nd baseline renal dysfunction, but not the presence of
oronary artery disease and revascularization completeness
rior to TAVI, determined a higher rise in biomarkers of
yocardial injury following the procedure. A higher degree
f myocardial injury was associated with a smaller improve-
ent or even a deterioration of LVEF and a higher cardiac
ortality at midterm follow-up, suggesting that CK-MB
nd especially cTnT values post-TAVI might become
mportant biomarkers in the evaluation of TAVI proce-
ures. Future studies including a larger number of patients
nd a longer follow-up will have to confirm these results and
urther determine the cardiac enzyme rise cutoff that should
e used for the diagnosis of periprocedural myocardial
nfarction following TAVI.
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